SCHEMBL4854097

SCHEMBL4854097

CCOP(=O)(/C=C/c1cn(-c2ccccc2)nc1OCc1ccc(OCc2nc(N3CCC(C(=O)O)CC3)sc2C)c(OC)c1)OCC

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 5/20 0.35
RAB9A P51151 3/20 0.35
GAA P10253 1/20 0.35
F2 P00734 1/20 0.34
F10 P00742 1/20 0.34
MAPT P10636 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 2/20 0.33
POLB P06746 2/20 0.33
ALDH1A1 P00352 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 1/20 0.33
PKM P14618 1/20 0.33
S1PR1 P21453 1/20 0.32
S1PR5 Q9H228 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4854119 1.00 TP53 (0.35) TP53SMN1; SMN2NPC1RAB9AGAA
SCHEMBL4847940 0.95 ALDH1A1 (0.36) TP53SMN1; SMN2NPC1RAB9AGAA
SCHEMBL4847933 0.95 ALDH1A1 (0.36) TP53SMN1; SMN2NPC1RAB9AGAA
SCHEMBL4846394 0.85 ALDH1A1 (0.40) TP53SMN1; SMN2NPC1RAB9AGAA
SCHEMBL4846073 0.84 MEN1 (0.38) TP53NPC1RAB9AGAAF2
SCHEMBL4846013 0.84 MEN1 (0.38) TP53NPC1RAB9AGAAF2
SCHEMBL4848785 0.83 KDM4E (0.41) TP53SMN1; SMN2GAAF2MAPT
SCHEMBL4848818 0.83 KDM4E (0.41) TP53SMN1; SMN2GAAF2MAPT
SCHEMBL4850379 0.80 PPARG (0.38) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL4850369 0.80 PPARG (0.38) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 TP53 4408/4885SMN1; SMN2 4339/4885NPC1 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.